Holen Sie sich die Stockscreener-App
0.4313
5.14%
0.0211
Handel nachbörslich:
.41
-0.0213
-4.94%
BiomX Inc Aktie (PHGE) Neueste Nachrichten
What analysts say about BiomX Inc. stockSkyrocketing returns - jammulinksnews.com
Is BiomX Inc. a good long term investmentFree Investment Risk Control - jammulinksnews.com
What drives BiomX Inc. stock priceSpectacular growth rates - jammulinksnews.com
BiomX Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - jammulinksnews.com
Should I buy BiomX Inc. stock before earningsHigh Return Stock Alerts - Newser
How BiomX Inc. stock performs during market volatilityFree Signals Group - Newser
What makes BiomX Inc. stock price move sharplyFree Access to Stock Community - Newser
Why BiomX Inc. stock attracts strong analyst attentionCapital Efficient Investment Tips - Newser
BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins - Investing.com Canada
BiomX doses first subject in Phase IIb trial of cystic fibrosis treatment - Yahoo Finance
BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target - Investing.com India
BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target By Investing.com - Investing.com South Africa
BiomX Stock Drops 7.23% Despite Phase 2b Trial Milestone - AInvest
BiomX announces successful initiation of Phase 2b trial - TipRanks
Market Alert: BiomX Trading Surges Following Phase 2b Trial Initiation in Cystic Fibrosis Program - openPR.com
Biomx Inc. shares fall 5.21% after-hours following the initiation of Phase 2b trial for BX004. - AInvest
BiomX Initiates Phase 2b Trial for BX004, a Phage Therapy Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients. - AInvest
Biomx Inc. Announces Successful Initiation of Phase 2B Trial with First Patient Dosed in Bx004 Program in Patients with Cystic Fibrosis - MarketScreener
BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy - Investing.com Australia
BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment - MSN
BiomX Doses First Patient in Phase 2b of Cystic Fibrosis Trial - MarketScreener
BiomX begins phase 2b trial for phage therapy targeting CF infections - Investing.com Australia
BiomX begins phase 2b trial for phage therapy targeting CF infections By Investing.com - Investing.com South Africa
BiomX Inc. Initiates First Patient Dosing in Phase 2b Trial for BX004 Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients - Nasdaq
BiomX Announces Successful Initiation of Phase 2b Trial - GlobeNewswire
Breakthrough Cystic Fibrosis Treatment Enters Phase 2b Trial After 14% Complete Infection Clearance - Stock Titan
BiomX (NYSEMKT:PHGE) Trading Down 43.3% – Here’s What Happened - Defense World
BiomX Publishes Promising Phase 1b/2a Trial Results - TipRanks
BiomX’s “Bacteria-Eating Virus” Therapy Shows 500-Fold Reduction in Deadly CF Infections: Company Announces Major Scientific Validation in Key Publication - newsblaze.com
BiomX announces publication on BX004 Phase 1b/2a Part 1 data - TipRanks
BiomX Announces Publication in Nature Communications of - GlobeNewswire
Nature Communications Validates BiomX's Breakthrough: 500-fold Bacteria Reduction in Cystic Fibrosis Trial - Stock Titan
Red White & Bloom Brands Provides Update on Status of Annual Filings - The Globe and Mail
This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret - FinancialContent
This $13M Biotech Has $40M In Pentagon Funding Here's Why Biomx Could Be Biotech's Best-Kept Secret - MenaFN
PHGE SEC FilingsBiomx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections - citybuzz -
BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says - FinancialContent
BiomX Highlights Progress in Phage Therapy Advancements - TipRanks
BiomX (NYSEAMERICAN:PHGE) Shares Down 4.3% – Here’s What Happened - Defense World
Biomx stock plunges to 52-week low, hitting $0.47 By Investing.com - Investing.com South Africa
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):